AGO2 and lung adenocarcinoma: Moreover, analyses of AGO2 protein levels in the public database of Clinical Proteomic Tumor Analysis Consortium (CPTAC) revealed a decrease in both lung adenocarcinoma (n = 111) and lung squamous cell carcinoma samples (n = 110) (Figure S4I–K, Supporting Information).